DR MARKUS SKRIFVARS (Orcid ID : 0000-0002-0341-0262)

DR YASEEN ARABI (Orcid ID : 0000-0001-5735-6241)

Article type : Clinical investigation

Corresponding author mail id: markus.skrifvars@hus.fi

Erythropoietin in traumatic brain injury associated acute kidney injury - A randomised controlled trial

Short title: Erythropoietin in kidney and traumatic brain injury

Markus B Skrifvars^{1,2,3}, Elizabeth Moore¹, Johan Mårtensson⁴, **Michael Bailey**¹, Craig French⁵, Jeffrey Presneill⁶, Alistair Nichol^{1,7,8,9}, Lorraine Little¹, Jacques Duranteau¹⁰, Olivier Huet¹¹, Samir Haddad¹², Yaseen Arabi¹², Colin McArthur¹³, David J Cooper^{1,9}, **Rinaldo Bellomo**^{1,14}, The EPO-TBI Investigators and the ANZICS Clinical Trials Group.

1. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
2. Division of Intensive Care, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and University of Helsinki, Finland
3. Department of Emergency Medicine and Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
4. Department of Physiology and Pharmacology, Section of Anaesthesia and Intensive Care, Karolinska Institutet, Stockholm, Sweden
5. Department of Intensive Care, Western Health, Melbourne, Victoria, Australia
6. Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia
7. School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland
8. St Vincent's University Hospital, Dublin, Ireland

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/aas.13244](https://doi.org/10.1111/aas.13244)

This article is protected by copyright. All rights reserved

9. Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria, Australia
10. Department of Anaesthesia and Intensive Care, Hôpitaux universitaires Paris Sud (HUPS), Université Paris Sud XI, France
11. Département d'anesthésie-réanimation, Hopital de la Cavale Blanche, Boulevard Tanguy Prigent, CHRU de Brest, Université de Bretagne Occidentale, Brest, France
12. King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
13. Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand
14. Department of Intensive Care, Austin Health, Melbourne, Victoria, Australia

For the EPO-TBI investigators and the ANZICS Clinical Trials Group

Corresponding author:

Dr Markus Skrifvars

Department of Emergency Medicine and Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

PB 340, 00029 HUS

Helsinki University Hospital, Helsinki, Finland

Funding:

EPO-TBI was supported by grants from the National Health and Medical Research Council of Australia (grant 545902) and the Transport Accident Commission of Victoria (grant D162). Markus Skrifvars has received personal research funding from Medicinska Understödsforeningen Liv och Hals, Finska Läkaresällskapet and Svenska Kulturfonden. Alistair Nichol has received support from the Health Research Board of Ireland.

Conflicts of interest:

Markus Skrifvars reports having received a research grant from GE Healthcare, travel reimbursements and lecture fees from Orion Pharma, COVIDIEN, Astellas Pharma and Axis-Shield. All other authors report that they have no conflicts of interest.

Abstract

Background

Acute kidney injury (AKI) in traumatic brain injury (TBI) is poorly understood and it is unknown if it can be attenuated using erythropoietin (EPO).

Methods

Pre-planned analysis of patients included in the EPO-TBI (ClinicalTrials.gov NCT00987454) trial who were randomised to weekly EPO (40,000 units) or placebo (0.9% sodium chloride) subcutaneously up to three doses or until intensive care unit (ICU) discharge. Creatinine levels and urinary output (up to seven days) were categorised according to the Kidney Disease Improving Global Outcome (KDIGO) classification. Severity of TBI was categorised with the International Mission for Prognosis and Analysis of Clinical Trials in TBI.

Results

Of 3,348 screened patients, 606 were randomized and 603 were analysed. Of these, 82 (14%) patients developed AKI according to KDIGO [60 (10%) with KDIGO 1, 11 (2%) patients with KDIGO 2, and 11 (2%) patients with KDIGO 3]. Male gender (hazard ratio [HR] 4.0 95% confidence interval [CI] 1.4-11.2, $p=0.008$) and severity of TBI (HR 1.3 95% CI 1.1-1.4, $p<0.001$ for each 10% increase in risk of poor six month outcome) predicted time to AKI. KDIGO stage 1 (HR 8.8 95% CI 4.5-17, $p<0.001$), KDIGO stage 2 (HR 13.2 95% CI 3.9-45.2, $p<0.001$) and KDIGO stage 3 (HR 11.7 95% CI 3.5-39.7, $p<0.005$) predicted time to mortality. Erythropoietin did not influence time to AKI (HR 1.08 95% CI 0.7-1.67, $p=0.73$) or creatinine levels during ICU stay ($p=0.09$).

Conclusions

Acute kidney injury is more common in male patients and those with severe compared to moderate TBI and appears associated with worse outcome. Erythropoietin does not prevent AKI after TBI.

Key words: acute kidney injury, creatinine, critical care, erythropoietin, renal insufficiency, traumatic brain injury

Editorial Comment

Erythropoietin, as a potent hormone that the body releases in response to some forms of stress, has been tested as a potentially protective treatment substance in different clinical

1 contexts. In this post-hoc subgroup analysis from an earlier trial, erythropoietin did not
2 appear to alter risk for kidney injury in traumatic brain injury patients.

11 **Introduction**

12 Traumatic brain injury (TBI) is a rising global health concern affecting especially the younger
13 population and results in both high mortality and, in many cases, life-long morbidity and
14 considerable treatment costs ¹⁻³. Severely injured TBI patients require treatment in an
15 intensive care unit (ICU) ⁴. During ICU care, TBI patients are at risk of developing
16 complications such as various degrees of organ failure ⁵. One serious complication is acute
17 kidney injury (AKI) which has been shown to occur in 18-36% of trauma patients treated in
18 the ICU ^{6,7}. Severity of AKI may range from a momentary decrease in urinary output or a
19 slight increase in a creatinine, to complete anuria and the need for renal replacement
20 therapy ⁷.

21 Recombinant erythropoietin (EPO) has been shown to have renal protective effects in
22 experimental studies ⁸⁻¹⁰. The use EPO for prevention of AKI has been studied in patients
23 undergoing cardiac surgery and following renal transplantation, but thus far the data are
24 conflicting ¹¹⁻¹⁴. No studies have assessed the effect of EPO on kidney function in patients
25 with trauma ¹⁵. Accordingly, we aimed to assess the incidence and factors increasing the
26 likelihood as well as survival association of AKI in patients with moderate to severe TBI.

1 Secondly, we studied the effect of EPO on kidney function by comparing the occurrence
2 of AKI using the KDIGO classification and creatinine levels in patients treated with either
3 EPO or placebo.

13 **Methods**

14 The EPO-TBI study was an international randomized controlled trial conducted in multiple
15 centres in Australia, New Zealand, Saudi-Arabia, France, Finland, Ireland and Germany
16 between May 3, 2010 and Nov 1, 2014 ¹⁶. All patients treated in the ICU for moderate or
17 severe TBI were screened for eligibility (Supplementary Figure 1). Patients with end-stage
18 renal failure receiving chronic dialysis were excluded from the trial. Enrolled patients
19 received either weekly doses of 40,000 IU of subcutaneous epoetin alfa (Eprex Janssen-Cilag
20 Pty Ltd, Titusville, NJ, USA) or placebo (0.9% sodium chloride). The randomisation process
21 and administration of drug has been described previously¹⁵. The administration of EPO
22 continued until patients had received a maximum of three doses, or until the patients was
23 discharged from the ICU ^{17,18}. A consort checklist for the reporting of the current study is
24 included in the Supplementary Materials. The EPO-AKI sub-study was a pre-planned study
25 and the protocol (a part of the original EPO-AKI protocol) is included in the Supplementary
26 Materials.

Data collection

A web based case record form was used including detailed data on patient characteristics, injury mechanism, pre-hospital care and immediate hospital management¹⁷. Specifically, data enabling the calculation of the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT-TBI) risk for poor six-month outcome was included¹⁹. Trained assessors classified injury severity with Injury Severity Scores (ISS), Abbreviated Injury Scales (AIS) based on radiological findings and hospital notes. Serum creatinine were prospectively recorded daily until ICU discharge and urine output during the first seven days.

AKI based on the KDIGO classification

Stages of AKI according to KDIGO²⁰ were defined as follows:

Stage 1: A 1.5 to 1.9 fold increase in creatinine compared to the creatinine measured on hospital admission, an absolute increase $> 26.5 \mu\text{mol/l}$ over 48 hours or a urinary output of less than 0.5 ml/kg/hour for 6-12 hours.

Stage 2: A 2.0 to 2.9 fold increase in creatinine compared to the creatinine measured on hospital admission or a urinary output less than 0.5 ml/kg/hour for more than 12 hours.

Stage 3: A 3 fold increase in creatinine compared to creatinine measured on hospital admission, an increase in creatinine to more than $353.6 \mu\text{mol/l}$, urinary output of less than 0.3 ml/kg/hour for more than 24 hours, anuria for more than 12 hours or initiation of renal replacement therapy.

Daily data on creatinine levels were available during the whole ICU stay and thus, in our primary analysis we used AKI KDIGO stages defined by changes in creatinine during the whole ICU stay. We also reported AKI free ICU days up to 21 days. Data on urinary output according to the KDIGO stages were only available during the first 7 days of ICU care. Therefore, in a secondary analysis, we studied early AKI, defined by changes in either creatinine or UO occurring during the first 7 days in the ICU. Renal recovery was defined as the absence of any KDIGO stage 1-3 on the day of ICU discharge or at day seven. No data on creatinine or urinary output after ICU discharge are included in the analysis.

Study outcomes

The primary outcome of the current study was the presence and timing of KDIGO stages 1-3 based on creatinine levels during the whole ICU stay. A secondary outcome was KDIGO

1 stages 1-3 based on creatinine levels and urinary output during the first 7 days. Patient
2 outcomes included ICU, hospital and six-month survival. Neurological function at six months
3 was determined by an assessor blinded to treatment group using the Glasgow Outcome
4 Scale extended (GOSE). The GOSE ranges from 1-8 with good outcome defined as a GOSE
5 score of 5-8.

6 7 *Sample size analysis*

8 Prior to the study initiation it was estimated that the incidence of AKI (KDIGO 1-3 compared
9 to no KDIGO class) would be around 9%. Given this assessment, a trial with 287 patients in
10 each group was estimated to have an 86% power to detect a change from 9% to 3% with a
11 two sided p-value 0.05. The EPO TBI trial enrolled 602 patients.

12 13 *Statistical analysis*

14 Categorical data are presented as counts and percentages and are compared using chi-
15 square test. Numerical data are presented as medians and interquartile range (IQR) in
16 parenthesis. Parametric data is compared with a Student's T test and non-parametric data
17 with the Mann-Whitney U test (two groups) or Kruskal-Wallis test (more than two groups).
18 Cox regression analysis was used to assess independent predictors of time to development
19 of AKI and patient survival at six months. Covariates included in the analysis of the
20 development of AKI included factors that had a p-value less than 0.1 in the univariate
21 analysis. Covariates included in the mortality analysis included covariates pre-specified in
22 our statistical analysis plan and included age, presence of hypoxia (oxygen saturation less
23 than 90%) or hypotension (systolic blood pressure less than 90 mmHg), intracranial mass
24 lesion, abnormal pupils (not equal or not reactive) and geographical region (Australia and
25 New Zealand, Saudi-Arabia or Europe) ²¹. The presence of KDIGO class was included as a
26 time dependent covariate and thus included transition between KDIGO states. Kaplan-Meier
27 curves for patients with AKI and those without were compared with a log-rank test.
28 Creatinine levels over time were compared with a mixed model with a diagonal covariance
29 structure, including time, treatment (EPO or placebo) and the interaction between time and
30 treatment. Statistical analysis was performed with SPSS version 22.0 (IBM Corp. Released
31 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) and SAS
32 version 9.4 (SAS Institute Inc., Cary, NC, USA).

Ethical assessment, consent and trial registration

The EPO-TBI study was approved by ethical committees at all study sites. Informed consent was obtained from the patient's next of kin or legal representative prior to study inclusion according to local ethical requirement. The trial was registered at ClinicalTrials.gov (NCT00987454), the Australian and New Zealand Clinical Trials Registry (ACTRN12609000827235), and European Drug Regulatory Authorities Clinical Trials (011-005235-22)

Results

Incidence of AKI during the first seven days and ICU stay

A total of 606 patients were included in the EPO-TBI trial (Fig. 1). Consent was withdrawn in three patients, therefore this analysis included a total of 603 patients. During the whole ICU stay, 82 (14%) patients developed AKI based on changes in creatinine (Fig.1). Sixty patients (10%) had a KDIGO stage of 1, 11 (2%) a KDIGO stage of 2, and 11 (2%) a KDIGO stage of 3 (Fig. 1). Median time to the highest KDIGO day was 6 days (IQR 4-9). Of the 82 patients with AKI, 59 (72%) had renal recovery prior to ICU discharge. Eight (1.3%) patients received RRT (seven during ICU stay) and of these, seven (88%) were alive at six months. The median time to initiation of RRT was 8 days (IQR 5-11) and in one patient, RRT was initiated on the day of ICU admission. During the first seven days, 210 (35%) patients developed AKI according to UO, 29 (5%) according to creatinine changes and 23 (4%) according to both creatinine and UO changes (Supplementary Fig. 1).

Admission risk factors for acute kidney injury

There were several differences in both patient, injury and treatment characteristics between patients that developed and those who did not develop AKI during ICU stay (Supplementary Table 1). Notably, patients with AKI were more commonly of male gender; had a higher body weight and more severe brain injury (Supplementary Table 1). On Cox regression analysis, independent predictors of time to development of AKI were male gender (HR 4.0 95% CI 1.4-11.2, $p=0.008$), and severity of TBI according to the IMPACT model (per 10% increase in risk of poor outcome, HR 1.25 95% CI 1.1-1.4, $p<0.001$) (Table 1).

Risk factors for AKI on day 3

In a COX regression model for time to AKI later than day 3, excluding those who had died or developed AKI before day three, several factors were identified; Male gender (HR 7.2 95% CI 1.7-29.9, $p=0.007$), TBI severity (per 10% increase in risk of poor outcome HR 1.2 95% CI 1.1-1.4, $p=0.007$) and the use of therapeutic hypothermia on days 1-2 (HR 2.6 95% CI 1.5-4.5, $p=0.001$) were independently associated with time to development of AKI after day 3. The use of EPO was not associated with time to AKI (HR 0.9 95% CI 0.6-1.5, $p=0.70$) (Supplementary Table 2).

Association of AKI with outcome

Patients with AKI (any KDIGO stage 1-3 during their ICU stay) had a higher ICU mortality (32% compared to 6%, $p<0.001$), hospital mortality (33% compared to 8%, $p<0.001$) and six-month mortality (34% compared to 10%, $p<0.001$) (Supplementary Table 3). Prior to day three, 26 patients had died and 9 patients had developed AKI. Survival curves of patients who had developed AKI and where alive at day three are shown in Fig. 2. Median stay in the ICU was longer in patients with AKI (15 IQR 8-25) compared to those without AKI (12 IQR 7-20) ($p=0.005$). However, median hospital length of stay was not different between patients with AKI (28 IQR 11-49) and those without (25 IQR 15-43) ($p=0.91$) (Supplementary Table 3). Similar findings were seen in patients with AKI occurring during the first seven days (Supplementary Table 4). Good neurologic recovery defined according to the GOSE scale occurred in 31 (38%) out of 82 AKI patients compared to 299 (58%) of 514 non-AKI patients ($p<0.001$).

In a Cox regression model including KDIGO class as a time-dependent covariate, all three KDIGO stages were related to six-month mortality (Table 2). Other significant predictors of

increased mortality were age (HR 1.04 95% CI 1.02-1.05, $p<0.001$), abnormal pupils (HR 2.0 95% CI 1.2-3.3, $p=0.01$) while treatment with EPO (HR 0.61 95% CI 0.38-0.96, $p=0.03$) predicted decreased mortality. Similar findings were seen using AKI occurring during the first seven days (Supplementary Table 5).

Effect of erythropoietin on AKI

The cumulative number of patients with AKI treated with EPO and placebo in the study and over time in the ICU are shown in Fig. 1, Fig.3 and Supplementary Fig.1. In Cox regression analysis the use of EPO was not found to influence time to development of AKI during the whole ICU stay (HR 0.99 95% CI 0.96-1.03, $p=0.56$) or during the first seven days (HR 1.01 95% CI 0.79-1.28, $p=0.96$). Creatinine levels over time are shown in Supplementary Fig.3. There were no differences in creatinine values over time in patients treated with EPO compared to placebo ($p=0.09$) nor were there any interactions between intervention (EPO or placebo) with time ($p=0.99$). There was no difference in AKI free days between EPO treated patients (median 11 days, IQR 5-18) compared to placebo treated patients (median 11, IQR 5-19) ($p=0.95$).

Discussion

We studied the EPO-TBI trial population to assess the incidence and outcome associations of AKI in patients with TBI admitted to ICU. Moreover, we aimed to test whether EPO treatment was associated with any evidence of a renal protective effect. We found that AKI as defined by the KDIGO criteria based on creatinine levels occurred in one in seven patients. Acute kidney injury based on either urinary output or creatinine levels during the first seven days was more common and occurred in 40% of patients. All forms of AKI had an independent association with long-term mortality, but the confidence intervals were wide. Finally, the use of EPO did not provide any protection from AKI.

The incidence of AKI was comparable to previous studies conducted in patients with trauma and TBI. Eriksson and colleagues reported the development of AKI in 103 (25%) patients in a sample of 413 ICU patients admitted following trauma. In a large study involving registry data of trauma patients admitted to the ICU ⁷ Bagshaw and colleagues reported an AKI

1 incidence rate of 18% during the first 24 hours⁶. Gomes and colleagues observed AKI in 50%
2 of trauma patients admitted to the ICU²². Noteworthy is that the current study, due to its
3 design, excluded some categories of patients in whom AKI might be even more common.

4 All stages of AKI were associated with a marked increase in mortality compared to patients
5 without AKI. Previous studies including patients with all types of trauma, have shown similar
6 findings, but data in patients with TBI have are limited^{6,7,23,24}. One possible mechanism for
7 the increase in mortality in TBI is aggravated cerebral oedema due to changes in
8 osmolality²⁵. In a recent study Siew and colleagues showed that among ICU patients with
9 shock and respiratory failure, KDIGO stage 2 and 3 are significant risk factors for both
10 delirium and coma (25). Interestingly, the use of RRT has been shown to be associated with
11 a very high mortality after TBI²⁵. This was not the case in the current study, as all but one of
12 eight patients that received RRT survived.

13 The current study identified several known markers of increased risk of AKI including male
14 gender. This observation may be explained by differences in weight and muscle mass
15 between males and females: a greater increase in creatinine in males may occur without a
16 true decrease in renal function. The current study also suggested an association between
17 the use of therapeutic hypothermia (TH) and increased likelihood of AKI. It is possible that
18 vasoconstriction, induced by hypothermia, reduces renal blood flow²⁶. A meta-analysis
19 including mainly patients resuscitated from cardiac arrest suggested no difference in the
20 prevalence of AKI in between TH and normothermia²⁷. On the other hand in a sub-study
21 from the Hypothermia and Cardiac Arrest trial the use of hypothermia was associated with a
22 delay in renal recovery²⁸. The study on the use of early induction of TH in TBI by Clifton and
23 colleagues showed no difference in creatinine levels between groups but did show an
24 increased use of intravenous fluids with TH²⁹.

25 Despite multiple animal studies suggesting positive effects on the kidney, we did not find
26 that EPO protected patients from AKI³⁰. The use of EPO in animal models has been shown
27 to decrease the extent of ischemia reperfusion injury, reduce the incidence of contrast
28 induced nephropathy and alleviate inflammation^{8-10,31}. The proposed protective
29 mechanisms include reduction of apoptotic cell death by several mechanisms^{32,33}. In the
30 ischemic kidney EPO enhances tissue regeneration, and neovascularisation^{34,35}. EPO also
31 suppresses the synthesis of TNF-alpha and interleukin-2 inflammatory markers which may
32 part in the development of AKI³³. In smaller clinical trials EPO has been shown to alleviate

early AKI after coronary artery bypass grafting³⁶. Thus in trauma patients EPO could be expected to have some protective effects within 24-48 hours after injury. Despite experimental evidence, a lack in positive effects on renal function has been shown in patients undergoing kidney transplantation and in the current study, in TBI patients with trauma¹⁵. It needs to be noted that the renal endpoints we studied i.e. KDIGO although relevant, may be too crude to detect smaller changes in renal function. All in all our findings corroborate that human AKI is much more complex than in experimental AKI.

Study strengths and limitations

The current study has a number of strengths. Centres from different health systems participated and therefore our results are likely to be generalizable. We also had detailed data on severity of traumatic brain injury and were able to adjust for that in the analysis.

Nonetheless several limitations need to be kept in mind. The study did not include data on specific medical conditions such as hypertension, diabetes mellitus or chronic kidney disease that may influence the development of AKI. In addition, the study did not include data on the use of medications, maintenance fluids, myoglobin levels, or therapies that might have influenced renal function. We only had data on urinary output during the first seven days. The UO data only included whether any of the KDIGO UO criteria occurred during the first seven days and did not include hourly or total diuresis. The study only includes short-term data on kidney function and thus we cannot comment on long term effects of EPO on kidney function. Finally, as the main sample size calculation was based on an assumed change in neurologically intact survivors at six months between the EPO and placebo groups, this sub-study may be underpowered to detect clinically meaningful differences in the more severe forms of AKI such as the need for RRT in TBI patients.

Conclusion

Within this RCT including patients with moderate to severe TBI, AKI was independently associated with mortality. We identified several factors associated with increasing the risk of AKI including increasing patient weight, male gender, more severe TBI, more severe admission illness severity, and the use of therapeutic hypothermia. Contrary to our hypothesis and despite compelling animal evidence, the use of EPO did not attenuate renal injury in this population.

Author Manuscript

Authors contributions: The current post-hoc analysis was planned by MS, EM, JM, MB, CF, AN, DJC and RB. MS, EM, MB, CF, JP, AN, LL, JD, OH, SH, YA, CM, DJC, RB were a part of the

EPO-TBI study. MS take responsibility of the integrity of the data and drafted the first version of the manuscript. All authors have read and critically contributed to the final draft.

Author Manuscript

References

1. Myburgh JA, Cooper DJ, Finfer SR, Venkatesh B, Jones D, Higgins A, Bishop N, Higlett T, Australasian Traumatic Brain Injury Study Investigators for the A, New Zealand Intensive Care Society Clinical Trials G. Epidemiology and 12-month outcomes from traumatic brain injury in australia and new zealand. *J Trauma* 2008; 64: 854-62.
2. Roozenbeek B, Maas AI, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. *Nature reviews Neurology* 2013; 9: 231-6.
3. Raj R, Bendel S, Reinikainen M, Hoppu S, Luoto T, Ala-Kokko T, Tetri S, Laitio R, Koivisto T, Rinne J, Kivisaari R, Siironen J, Higgins A, Skrifvars MB. Temporal Trends in Healthcare Costs and Outcome Following ICU Admission After Traumatic Brain Injury. *Crit Care Med* 2018; 46: e302-e09.
4. Stocchetti N, Carbonara M, Citerio G, Ercole A, Skrifvars MB, Smielewski P, Zoerle T, Menon DK. Severe traumatic brain injury: targeted management in the intensive care unit. *Lancet Neurol* 2017; 16: 452-64.
5. Zygun D, Berthiaume L, Laupland K, Kortbeek J, Doig C. SOFA is superior to MOD score for the determination of non-neurologic organ dysfunction in patients with severe traumatic brain injury: a cohort study. *Crit Care* 2006; 10: R115.
6. Bagshaw SM, George C, Gibney RT, Bellomo R. A multi-center evaluation of early acute kidney injury in critically ill trauma patients. *Renal failure* 2008; 30: 581-9.
7. Eriksson M, Brattstrom O, Martensson J, Larsson E, Oldner A. Acute kidney injury following severe trauma: Risk factors and long-term outcome. *The journal of trauma and acute care surgery* 2015; 79: 407-12.
8. Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntas I, Karahan N, Okutan H. The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. *The Journal of surgical research* 2008; 149: 206-13.

- 1 9. Simon F, Scheuerle A, Calzia E, Bassi G, Oter S, Duy CN, Kick J, Bruckner UB, Radermacher P,
2 Schelzig H. Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion
3 injury. *Crit Care Med* 2008; 36: 2143-50.
- 4 10. Matejkova S, Scheuerle A, Wagner F, McCook O, Matallo J, Groger M, Seifritz A, Stahl B,
5 Vcelar B, Calzia E, Georgieff M, Moller P, Schelzig H, Radermacher P, Simon F. Carbamylated
6 erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney
7 ischemia/reperfusion injury. *Intensive Care Med* 2013; 39: 497-510.
- 8 11. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P. Epoetin
9 administrated after cardiac surgery: effects on renal function and inflammation in a randomized
10 controlled study. *BMC nephrology* 2012; 13: 132.
- 11 12. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence
12 of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical
13 trial of efficacy and safety. *Crit Care* 2013; 17: R254.
- 14 13. Dardashti A, Ederoth P, Algotsson L, Bronden B, Grins E, Larsson M, Nozohoor S, Zinko G,
15 Bjursten H. Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial).
16 *Anesthesiology* 2014; 121: 582-90.
- 17 14. Hafer C, Becker T, Kielstein JT, Bahlmann E, Schwarz A, Grinzoff N, Drzymala D, Bonnard I,
18 Richter N, Lehner F, Klempnauer J, Haller H, Traeder J, Fliser D. High-dose erythropoietin has no
19 effect on short- or long-term graft function following deceased donor kidney transplantation. *Kidney*
20 *international* 2012; 81: 314-20.
- 21 15. Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-
22 analysis. *BMC nephrology* 2017; 18: 14.
- 23 16. Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J,
24 Huet O, Mak A, McArthur C, Pettila V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R,
25 Investigators E-T, Group ACT. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind
26 randomised controlled trial. *Lancet* 2015; 386: 2499-506.
- 27 17. Nichol A, French C, Little L, Presneill J, Cooper DJ, Haddad S, Duranteau J, Huet O, Skrifvars M,
28 Arabi Y, Bellomo R, Investigators E-T, the A, New Zealand Intensive Care Society Clinical Trials G.
29 Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial. *Trials* 2015;
30 16: 39.
- 31 18. Lingsma HF, Roozenbeek B, Steyerberg EW, Murray GD, Maas AI. Early prognosis in
32 traumatic brain injury: from prophecies to predictions. *Lancet Neurol* 2010; 9: 543-54.
- 33 19. Marmarou A, Lu J, Butcher I, McHugh GS, Murray GD, Steyerberg EW, Mushkudiani NA, Choi
34 S, Maas AI. Prognostic value of the Glasgow Coma Scale and pupil reactivity in traumatic brain injury

- assessed pre-hospital and on enrollment: an IMPACT analysis. *Journal of neurotrauma* 2007; 24: 270-80.
20. Section 2: AKI Definition. *Kidney International Supplements*; 2: 19-36.
21. Presneill J, Little L, Nichol A, French C, Cooper DJ, Haddad S, Duranteau J, Huet O, Skrifvars M, Arabi Y, Bellomo R, Investigators E-T, Group ACT. Statistical analysis plan for the Erythropoietin in Traumatic Brain Injury trial: a randomised controlled trial of erythropoietin versus placebo in moderate and severe traumatic brain injury. *Trials* 2014; 15: 501.
22. Gomes E, Antunes R, Dias C, Araujo R, Costa-Pereira A. Acute kidney injury in severe trauma assessed by RIFLE criteria: a common feature without implications on mortality? *Scandinavian journal of trauma, resuscitation and emergency medicine* 2010; 18: 1.
23. Ala-Kokko T, Ohtonen P, Laurila J, Martikainen M, Kaukoranta P. Development of renal failure during the initial 24 h of intensive care unit stay correlates with hospital mortality in trauma patients. *Acta anaesthesiologica Scandinavica* 2006; 50: 828-32.
24. Brandt MM, Falvo AJ, Rubinfeld IS, Blyden D, Durrani NK, Horst HM. Renal dysfunction in trauma: even a little costs a lot. *J Trauma* 2007; 62: 1362-4.
25. Davenport A. Renal replacement therapy in the patient with acute brain injury. *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2001; 37: 457-66.
26. Broman M, Kallskog O. The effects of hypothermia on renal function and haemodynamics in the rat. *Acta physiologica Scandinavica* 1995; 153: 179-84.
27. Susantitaphong P, Alfayez M, Cohen-Bucay A, Balk EM, Jaber BL. Therapeutic hypothermia and prevention of acute kidney injury: a meta-analysis of randomized controlled trials. *Resuscitation* 2012; 83: 159-67.
28. Zeiner A, Sunder-Plassmann G, Sterz F, Holzer M, Losert H, Laggner AN, Mullner M. The effect of mild therapeutic hypothermia on renal function after cardiopulmonary resuscitation in men. *Resuscitation* 2004; 60: 253-61.
29. Clifton GL, Coffey CS, Fourwinds S, Zygun D, Valadka A, Smith KR, Jr., Frisby ML, Bucholz RD, Wilde EA, Levin HS, Okonkwo DO. Early induction of hypothermia for evacuated intracranial hematomas: a post hoc analysis of two clinical trials. *J Neurosurg* 2012; 117: 714-20.
30. Liu KD, Humphreys BD, Endre ZH. The ten barriers for translation of animal data on AKI to the clinical setting. *Intensive Care Med* 2017; 43: 898-900.
31. Wang G, Huang H, Wu H, Wu C, Xu Y, Wang L, Liu X, Wang C, Shen Y, Li D, Jing H. Erythropoietin attenuates cardiopulmonary bypass-induced renal inflammatory injury by inhibiting nuclear factor-kappaB p65 expression. *European journal of pharmacology* 2012; 689: 154-9.

- 1 32. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute
2 renal failure. *Am J Physiol* 1994; 266: F360-6.
- 3 33. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective
4 agent. *Anaesth Intensive Care* 2011; 39: 356-72.
- 5 34. Kang DH, Park EY, Yu ES, Lee YS, Yoon KI. Renoprotective effect of erythropoietin (EPO):
6 possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. *Kidney*
7 *international* 2005; 67: 1683.
- 8 35. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS. NF-
9 kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. *Exp*
10 *Hematol* 2002; 30: 1419-27.
- 11 36. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of
12 acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot
13 study. *Am J Nephrol* 2009; 30: 253-60.

Table 1 Multivariable analysis of admission factors related to development of time to acute kidney injury in patients with traumatic brain injury included in the erythropoietin in traumatic brain injury trial

Variable	Univariate HR (95% CI)	p-value	Multivariate HR (95% CI)	p-value
Patient weight	1.01 (1.001-1.02)	0.03	1.01 (0.99-1.02)	0.32
Male gender	3.99 (1.46-10.89)	0.007	4.02 (1.44-11.23)	0.008
Injury mechanism:				
Motorcycle accident	1.67 (0.94-2.97)	0.08	1.72 (0.95-3.11)	0.07
Pedestrian accident	1.44 (0.78-2.66)	0.24	1.67 (0.89-3.13)	0.11
TBI severity according to IMPACT risk of poor outcome (per 10%)	1.19 (1.07-1.33)	0.002	1.24 (1.10-1.40)	<0.001

APACHE II score	1.01 (0.98-1.04)	0.47	0.99 (0.96-1.03)	0.56
-----------------	------------------	------	------------------	------

Table 2 Independent predictors of mortality in patients included in the erythropoietin in traumatic brain injury trial including time to development and severity of acute kidney injury.

Variable	Univariate HR (95% CI)	p-value	Multivariate HR (95% CI	p-value
----------	---------------------------	---------	----------------------------	---------

Age	1.03 (1.02-1.05)	<0.001	1.04 (1.02-1.05)	<0.001
Hypotension	1.15 (0.72-1.84)	0.52	1.06 (0.65-1.75)	0.81
Hypoxia	1.31 (0.78-2.23)	0.31	1.44 (0.83-2.5)	0.20
No intracranial mass lesion	0.72 (0.43-1.23)	0.23	0.77 (0.45-1.3)	0.33
Pupils abnormal (not equal, non-reactive)	2.20 (1.37-3.52)	0.001	2.00 (1.21-3.3)	0.01
Region (Saudi-Arabia reference)				0.30
Australia and New Zealand	0.82 (0.53-1.28)	0.39	0.71 (0.22-2.32)	
Europe	1.05 (0.63-1.77)	0.84	0.57 (0.16-2.00)	
Moderate TBI	0.7 (0.4-1.22)	0.21	0.68 (0.38-1.2)	0.19
Acute Kidney Injury ¹				<0.001
KDIGO 1	8.61 (4.52-16.42)	<0.001	8.76 (4.51-16.99)	
KDIGO 2	14.24 (4.36-46.56)	<0.001	13.22 (3.87-45.16)	
KDIGO 3	8.61 (2.7-27.48)	<0.001	11.72 (3.46-39.68)	
Treatment with EPO	0.65 (0.41-1.02)	0.06	0.61 (0.38-0.96)	0.03

¹ The reference category is no AKI (Absence of KDIGO 1-3).

1
2
3
4
5 **Fig.1** Flow chart of patients included in the EPO-TBI trial and the development of various stages of
6 acute kidney injury based on changes in creatinine during ICU stay.

7
8 **Fig.2** Survival curves in 599 (excluding deaths prior to day 3) traumatic brain injury patients treated
9 in the intensive care unit indexed by the development of acute kidney injury before day 3 based on
10 creatinine and urinary output.

11
12 **Fig.3** The timing and cumulative cases of acute kidney in injury in patients treated with
13 erythropoietin or placebo in the erythropoietin in traumatic brain injury trial.

aas_13244_f1.tif

aas_13244_f2.png

aas_13244_f3.tif

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Skrifvars, MB;Moore, E;Martensson, J;Bailey, M;French, C;Presneill, J;Nichol, A;Little, L;Duranteau, J;Huet, O;Haddad, S;Arabi, Y;McArthur, C;Cooper, DJ;Bellomo, R

Title:

Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial

Date:

2019-02-01

Citation:

Skrifvars, M. B., Moore, E., Martensson, J., Bailey, M., French, C., Presneill, J., Nichol, A., Little, L., Duranteau, J., Huet, O., Haddad, S., Arabi, Y., McArthur, C., Cooper, D. J. & Bellomo, R. (2019). Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 63 (2), pp.200-207. <https://doi.org/10.1111/aas.13244>.

Persistent Link:

<http://hdl.handle.net/11343/284393>